Supplements
Effectiveness scored 40 due to RCTs confirming Setria GSH bioavailability (e.g., PubMed 24791752: 250-1000mg/day raised GSH stores 17-29% over 6 months) but zero support for cancer risk reduction—the key claim—with Recancostat study (Klin Padiatr 1999) showing no tumor prevention benefit. Detox/cellular protection has moderate preclinical/GSH-boost evidence but no strong clinical outcomes. Safety high (90) as oral RCTs report no serious adverse events; quality 70 for branded ingredients and puri
Average (57/100) - Effectiveness scored 40 due to RCTs confirming Setria GSH bioavailability (e.g., PubMed 24791752: 250-1000mg/day raised GSH stores 17-29% over 6 months) but zero support for cancer risk reduction—the key claim—with Recancostat study (Klin Padiatr 1999) showing no tumor prevention benefit. Detox/cellular protection has moderate preclinical/GSH-boost evidence but no strong clinical outcomes. Safety high (90) as oral RCTs report no serious adverse events; quality 70 for branded ingredients and purity claims without third-party seals. Overall 57 reflects promising antioxidant mechanism undermined by unproven disease claims and high cost ($2/serving).